Loading company…
Oryza researches and develops new and generic medicines with sustained and controlled release.
Founded in 2016 and based in Shenzhen, China, Oryza researches and develops new and generic drugs in several dosage forms, including solid, liquid, semi-solid, patch, and nanospray. Its products address conditions including diabetes, digestive and cardiovascular diseases, and cancer. The company has research facilities in Florida and offices in Beijing and Hong Kong. In December 2025, it raised Series C funding from China Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in